School of Chemical and Biotechnology, Shanmugha Arts, Science, Technology and Research Academy (SASTRA) University, Thanjavur, India.
Department of Neurovirology, National Institute of Mental Health and Neurosciences, Bangalore, India.
Int J Nanomedicine. 2014 Jan 28;9:627-34. doi: 10.2147/IJN.S53415. eCollection 2014.
Delayed onset of, and low magnitude of, protective immune responses are major drawbacks limiting the practical utility of plasmid vaccination against rabies. In this study we evaluated whether nanoformulation with the novel poly(ether imine) (PETIM) dendrimer can enhance the immunogenicity and efficacy of a plasmid-based rabies vaccine.
A plasmid vaccine construct (pIRES-Rgp) was prepared by cloning the full-length rabies virus glycoprotein gene into pIRES vector. Drawing upon the results of our previous study, a dendriplex (dendrimer-DNA complex) of pIRES-Rgp was made with PETIM dendrimer (10:1 w/w, PETIM:pIRES-Rgp). In vitro transfection was done on baby hamster kidney (BHK)-21 cells to evaluate expression of glycoprotein gene from pIRES-Rgp and PETIM-pIRES-Rgp. Subsequently, groups of Swiss albino mice were immunized intramuscularly with pIRES-Rgp or PETIM-pIRES-Rgp. A commercially available cell culture rabies vaccine was included for comparison. Rabies virus neutralizing antibody (RVNA) titers in the immune sera were evaluated on days 14, 28, and 90 by rapid fluorescent focus inhibition test. Finally, an intracerebral challenge study using a challenge virus standard strain of rabies virus was done to evaluate the protective efficacy of the formulations.
Protective levels of RVNA titer (≥0.5 IU/mL) were observed by day 14 in animals immunized with pIRES-Rgp and its dendriplex. Notably, PETIM-pIRES-Rgp produced 4.5-fold higher RVNA titers compared to pIRES-Rgp at this time point. All mice immunized with the PETIM-pIRES-Rgp survived the intracerebral rabies virus challenge, compared with 60% in the group which received pIRES-Rgp.
Our results suggest that nanoformulation with PETIM dendrimer can produce an earlier onset of a high-titered protective antibody response to a plasmid-based rabies vaccine. PETIM dendriplexing appears to be an efficacious nonviral delivery strategy to enhance genetic vaccination.
保护性免疫反应出现延迟且幅度较低,这是限制狂犬病质粒疫苗实际应用的主要缺陷。本研究旨在评估新型聚醚亚胺(PETIM)树枝状聚合物纳米制剂是否可以增强基于质粒的狂犬病疫苗的免疫原性和效力。
通过将全长狂犬病病毒糖蛋白基因克隆到 pIRES 载体中,制备了质粒疫苗构建体(pIRES-Rgp)。根据我们之前的研究结果,用 PETIM 树枝状聚合物(10:1 w/w,PETIM:pIRES-Rgp)制备了 pIRES-Rgp 的树枝状聚合物-DNA 复合物(dendriplex)。在婴儿仓鼠肾(BHK-21)细胞上进行体外转染,以评估 pIRES-Rgp 和 PETIM-pIRES-Rgp 中糖蛋白基因的表达。随后,将一组瑞士白化病小鼠肌肉内免疫 pIRES-Rgp 或 PETIM-pIRES-Rgp。同时包含一种市售细胞培养狂犬病疫苗作为比较。用快速荧光灶抑制试验(RFFIT)在第 14、28 和 90 天评估免疫血清中的狂犬病病毒中和抗体(RVNA)滴度。最后,使用狂犬病病毒标准攻击毒株进行脑内攻击研究,以评估制剂的保护效力。
pIRES-Rgp 及其树枝状聚合物的免疫动物在第 14 天观察到保护性 RVNA 滴度(≥0.5 IU/mL)。值得注意的是,在这个时间点,PETIM-pIRES-Rgp 产生的 RVNA 滴度比 pIRES-Rgp 高 4.5 倍。与接受 pIRES-Rgp 的组相比,用 PETIM-pIRES-Rgp 免疫的所有小鼠均在脑内狂犬病病毒攻击中存活。
我们的结果表明,用 PETIM 树枝状聚合物纳米制剂可以产生针对基于质粒的狂犬病疫苗的更早出现和更高滴度的保护性抗体反应。PETIM 树枝状聚合物的交联似乎是一种有效的非病毒传递策略,可增强基因疫苗接种。